Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H14N4O2 |
| Molecular Weight | 234.2545 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(C)=NN1C2=NC(C)=CC(OC)=N2
InChI
InChIKey=RHAXSHUQNIEUEY-UHFFFAOYSA-N
InChI=1S/C11H14N4O2/c1-7-5-9(16-3)13-11(12-7)15-10(17-4)6-8(2)14-15/h5-6H,1-4H3
| Molecular Formula | C11H14N4O2 |
| Molecular Weight | 234.2545 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Epirizole (also known as Mepirizole) is a nonsteroidal anti-inflammatory drug developed for the treatment of such conditions as chronic rheumatoid arthritis. Although the drug was tested in a clinical trial, its current status is unknown and is supposed to be discontinued. Epirizole is known to be a duodenal ulcerogen, and its effect is mediated by generation of ROS.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
600 mg 3 times / day multiple, oral Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: |
Other AEs: Stomachache, Nausea... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Nausea | 600 mg 3 times / day multiple, oral Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: |
|
| Stomachache | 600 mg 3 times / day multiple, oral Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Gastric antisecretory and anti-ulcer effect of ME3407, a new benzimidazole derivative, in rats. | 2004 |
|
| Synthesis, crystal structure, magnetic properties, and theoretical studies of [(Cu(mepirizole)Br)2(mu-OH)(mu-pz)] (mepirizole=4-methoxy-2-(5-methoxy-3-methyl-1H-pyrazol-1-yl)-6-methylpyrimidine; pz=pyrazolate), a novel mu-pyrazolato-mu-hydroxo-dibridged copper(II) complex. | 2003-12-15 |
|
| Study of the modifications caused by cisplatin, transplatin, and Pd(II) and Pt(II) mepirizole derivatives on pBR322 DNA by atomic force microscopy. | 2002-10-01 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:36:12 GMT 2025
by
admin
on
Mon Mar 31 17:36:12 GMT 2025
|
| Record UNII |
3B46O2FH8I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
18694-40-1
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
C76075
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
EPIRIZOLE
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
SUB13691MIG
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
D004840
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
2929
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL1411693
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
242-507-1
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
3B46O2FH8I
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
m4947
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | Merck Index | ||
|
1029
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
100000078948
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
DTXSID4045422
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
3242
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY | |||
|
DB08991
Created by
admin on Mon Mar 31 17:36:12 GMT 2025 , Edited by admin on Mon Mar 31 17:36:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |